PRA Health Sciences shook off the effects of a surging dollar to pull off 7% revenue growth in the first quarter, kicking off the year with its largest ever backlog.
Biocon, India's pre-eminent biotech company, is planning to spin out its in-house CRO in an Indian IPO, a move that shines a light on the country's evolving industry.
Catalent came through with a big earnings boost last quarter, shaking off some deleterious currency fluctuations and cutting costs.
Montreal-headquartered CRO JSS Medical Research is reaching into India, buying out Max Neeman International as it expands around the globe.
Awaiting the closure of a wide-ranging deal with Quest Diagnostics, Quintiles is expanding its capabilities in bioanalytics, opening a new outpost in Europe for lab tests.
Contract drug developer AMRI, on the mend after a series of setbacks, posted a 38% sales boost to start the year, but the costs of an ongoing transition dragged it into the red for yet another quarter.
CRO giant Parexel posted flat revenue last quarter, paring back its full-year expectations in the face of currency headwinds and client delays.
Allergan has reached out to CRO ImageIQ to support its development of a new treatment for bladder disease, recruiting the imaging specialist to pitch in on a new clinical trial.
WuXi PharmaTech's CEO has teamed up with a major investor in an attempt to take the CRO private, pitching a buyout that would give the Chinese company's shareholders a 16.2% premium.
Preclinical research giant Charles River Laboratories posted 7% revenue growth in the first quarter, absorbing the blow of a tough currency translation as it deepens its focus on drug discovery services.
Quintiles' banner business came up short in the first quarter, as currency fluctuations bit into revenue and led the world's largest CRO to dial down its full-year guidance.
Icon came through with double-digit revenue growth in the first quarter, but currency fluctuations have the Irish CRO scaling back its expectations for the full year.
CRO INC Research boosted its sales by 14.5% in the first quarter, returning to profitability as it blueprints a big year.
BioClinica has poached an Oracle exec to lead its banner eClinical division, part of its long-term expansion efforts.
Months removed from buying its way into the world of Big Data genomics, Chinese CRO WuXi PharmaTech has partnered up with DNAnexus to take its technology to the cloud.
Indian biotech giant Biocon is planning to take Syngene, its in-house CRO, public in an IPO on the local exchange.
Biopharma production specialist Sartorius Stedim Biotech has acquired BioOutsource, a U.K. CRO focused on the growing demand for knockoffs of top-selling biologics.
PPD has opened a new central lab facility in Shanghai, expanding its testing services into China as it stretches out around the globe.
Catalent doubled its capacity at a Kentucky manufacturing facility, wrapping up a $52 million project with plans to add about 140 new workers.
Quintiles is further entrenching itself in Latin America, striking a deep-rooted alliance with a research site in Buenos Aires to widen its global network of trusted partners.